PROTAC Compounds Targeting Androgen Receptor Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer and related conditions, such as Kennedy's Disease, face challenges due to resistance development and the need for effective therapies targeting the androgen receptor (AR) for aberrant regulation and activity.
Innovation Solution
Development of bifunctional compounds, specifically proteolysis targeting chimeric (PROTAC) compounds, which recruit the androgen receptor to E3 ubiquitin ligases like Von Hippel-Lindau (VHL) for ubiquitination and degradation, utilizing a structure comprising an AR binding moiety linked to a VHL binding moiety to facilitate targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for prostate cancer are used to inhibit androgen receptor function, then androgen-AR axis is inhibited, but resistance develops and disease progresses
Solution Approach 1:
The patent extracts the androgen receptor protein itself as the target for elimination, rather than merely inhibiting its function. By recruiting the ubiquitin-proteasome system to degrade the AR protein, the treatment removes the source of resistance development, thereby extending the duration of therapeutic response.
Solution Approach 2:
The patent changes the fundamental parameter of AR management from functional inhibition to complete protein degradation. This parameter change from blocking activity to eliminating the protein itself prevents resistance mechanisms that arise from functional inhibition, thereby improving long-term treatment reliability.
2Reliability
If bifunctional PROTAC compounds are used to recruit androgen receptor to E3 ubiquitin ligase for degradation, then targeted protein degradation is achieved, but treatment approach complexity increases
Solution Approach 1:
The patent merges two distinct functional moieties into a single bifunctional PROTAC compound: an androgen receptor binding domain and a VHL E3 ubiquitin ligase binding domain. This merging enables the compound to simultaneously recruit both the target protein and the degradation machinery, achieving reliable targeted degradation despite the increased structural complexity.
Solution Approach 2:
The bifunctional PROTAC compound acts as an intermediary molecule that bridges the androgen receptor and the VHL E3 ubiquitin ligase. This intermediary facilitates the formation of a ternary complex, enabling targeted degradation while managing the complexity through a well-defined molecular architecture with linker regions connecting the two binding moieties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively modulate androgen receptor ubiquitination and degradation, offering a therapeutic approach for treating prostate cancer and Kennedy's Disease by enhancing treatment efficacy and overcoming resistance issues.
Implementation Method 1
recruit endogenous proteins, e.g., AR proteins, to E3 Ubiquitin Ligase for ubiquitination and degradation
Data Source
AI summary
The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.